Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib in Japanese Subjects With Advanced Solid Tumors or Biliary Tract Cancer
NCT03082053Phase 1Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of varlitinib in solid tumor and biliary tract cancer (BTC) (2 arms), sponsored by ASLAN Pharmaceuticals. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Maximum Tolerated Dose or Recommended Phase II Dose at 52 weeks. Started Jan 2017; status: completed.
02
Drugs
varlitinib
03
Conditions
solid tumorbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03082053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082053.